Company intelligence / Profile preview

Bio-ReCell

London, England, United Kingdombio-recell.com ↗

Ownership: Private
Employees: ~22
Development stage: Other

Overview

Bio-ReCell develops novel, non-magnetic, impurity-free technologies for isolating and activating specific cell types—primarily T-cells and stromal vascular fraction cells—for use in cell therapy manufacturing. Their solutions reduce processing times by up to 9 days per batch and lower overall manufacturing costs by 10% for T-cell therapies. The company’s products are designed to improve consistency, purity, and efficiency in the preparation of therapeutic cells.

Therapeutic areas: Other
Modalities: Cell therapyDevice (cell separation and activation kits)
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Bio-ReCell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bio-ReCell.

Explore the full profile